• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RBD-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern.

作者信息

Zhou Chuge, Zai Xiaodong, Zhou Ziqing, Li Ruihua, Zhang Yue, Li Yaohui, Yin Ying, Zhang Jun, Xu Junjie, Chen Wei

机构信息

Beijing Institute of Biotechnology, No. 20 Dongdajie Street, Fengtai District, 100071, Beijing, China.

出版信息

Signal Transduct Target Ther. 2021 Nov 10;6(1):390. doi: 10.1038/s41392-021-00798-8.

DOI:10.1038/s41392-021-00798-8
PMID:34759271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8578908/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7aa/8580989/71a38c6c3ec2/41392_2021_798_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7aa/8580989/71a38c6c3ec2/41392_2021_798_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7aa/8580989/71a38c6c3ec2/41392_2021_798_Fig1_HTML.jpg

相似文献

1
RBD-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern.RBD-sc-二聚体诱导了对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其关注变体的强大交叉中和作用。
Signal Transduct Target Ther. 2021 Nov 10;6(1):390. doi: 10.1038/s41392-021-00798-8.
2
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
3
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.COVID-19 恢复期个体中中和抗体的时间成熟提高了对流行的 SARS-CoV-2 变体的效力和广度。
Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2.
4
Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.BNT162b2疫苗诱导产生的针对真实B.1、B.1.1.7、B.1.351、B.1.525和P.1型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和抗体血清学调查
Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.
5
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.非住院 COVID-19 患者对 SARS-CoV-2 和季节性冠状病毒的抗体反应。
mSphere. 2021 Feb 24;6(1):e01145-20. doi: 10.1128/mSphere.01145-20.
6
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.用于治疗和预防 SARS-CoV-2 感染的中和单克隆抗体。
New Microbiol. 2021 Jul;44(3):135-144.
7
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
8
An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.SARS-CoV-2 血清学检测作为真实病毒中和的替代指标的评估。
Microbiol Spectr. 2021 Oct 31;9(2):e0105921. doi: 10.1128/Spectrum.01059-21. Epub 2021 Oct 27.
9
Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.新型单克隆抗体和针对变异 SARS-CoV-2 的重组抗体
Front Immunol. 2021 Aug 30;12:715464. doi: 10.3389/fimmu.2021.715464. eCollection 2021.
10
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.接种 SARS-CoV-2 疫苗或感染一年后均可检测到强大的中和抗体水平。
Viruses. 2021 Oct 5;13(10):2003. doi: 10.3390/v13102003.

引用本文的文献

1
Glycosylated SARS-CoV-2 RBD Antigens Expressed in Glycoengineered Yeast Induce Strong Immune Responses Through High Antigen-Alum Adsorption.在糖基工程酵母中表达的糖基化严重急性呼吸综合征冠状病毒2受体结合域抗原通过高抗原-明矾吸附诱导强烈免疫反应。
Biomolecules. 2025 Aug 15;15(8):1172. doi: 10.3390/biom15081172.
2
Antigen-dependent modulation of immune responses to antigen-Fc fusion proteins by Fc-effector functions.抗原依赖性调节抗原-Fc 融合蛋白的免疫应答：Fc 效应功能的作用。
Front Immunol. 2023 Oct 5;14:1275193. doi: 10.3389/fimmu.2023.1275193. eCollection 2023.
3
Activation and induction of antigen-specific T follicular helper cells play a critical role in recombinant SARS-CoV-2 RBD vaccine-induced humoral responses.

本文引用的文献

1
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.体液免疫应答对循环 SARS-CoV-2 变体引发的灭活和 RBD-亚单位疫苗。
Cell Res. 2021 Jul;31(7):732-741. doi: 10.1038/s41422-021-00514-9. Epub 2021 May 21.
2
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
3
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
抗原特异性滤泡辅助性T细胞的激活和诱导在重组SARS-CoV-2 RBD疫苗诱导的体液免疫反应中起关键作用。
Mol Biomed. 2023 Oct 19;4(1):34. doi: 10.1186/s43556-023-00145-z.
4
Precise modification of the surface charge of antigen enhances vaccine immunogenicity.精确修饰抗原的表面电荷可增强疫苗的免疫原性。
Innovation (Camb). 2023 May 29;4(4):100451. doi: 10.1016/j.xinn.2023.100451. eCollection 2023 Jul 10.
5
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.接种疫苗诱导产生针对含奥密克戎的 SARS-CoV-2 变异株的广谱中和抗体。
Signal Transduct Target Ther. 2022 Apr 27;7(1):139. doi: 10.1038/s41392-022-00987-z.
通用设计的贝塔冠状病毒疫苗，用于预防 COVID-19、MERS 和 SARS。
Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28.
4
Site-specific glycan analysis of the SARS-CoV-2 spike.新冠病毒刺突蛋白的糖基化位点特异性分析。
Science. 2020 Jul 17;369(6501):330-333. doi: 10.1126/science.abb9983. Epub 2020 May 4.
5
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.酵母表达的严重急性呼吸综合征冠状病毒（SARS-CoV）刺突蛋白受体结合域的重组蛋白，以去糖基化形式作为SARS疫苗候选物。
Hum Vaccin Immunother. 2014;10(3):648-58. doi: 10.4161/hv.27464. Epub 2013 Dec 30.